Shares of Omnicell OMCL were flat in after-market trading after the company reported Q4 results.
Quarterly Results
Earnings per share were up 18.18% year over year to $0.91, which beat the estimate of $0.80.
Revenue of $249,202,000 rose by 0.37% from the same period last year, which beat the estimate of $245,500,000.
Guidance
Omnicell hasn't issued any earnings guidance for the time being.
The upcoming fiscal year's revenue expected to be between $1,900,000,000 and $2,000,000,000.
Details Of The Call
Date: Feb 01, 2021
Time: 04:30 PM
ET Webcast URL: https://edge.media-server.com/mmc/p/9s5ry22x
Recent Stock Performance
Company's 52-week high was at $128.41
Company's 52-week low was at $54.24
Price action over last quarter: Up 41.84%
Company Overview
Omnicell provides automation and business analytics software for healthcare providers. The firm operates in two segments: automation and analytics and medication adherence. The automation and analytics segment manufactures medication dispensing systems, pharmacy inventory management systems, and related software. This segment contributes the majority of revenue. The medication adherence segment sells products like consumable medication blister cards and packaging equipment to help administer medication outside of a hospital setting. Omnicell generates the vast majority of its revenue in the United States.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
